HB3583 - Affordable Drug Manufacturing Act

• Creates the Affordable Drug Manufacturing Act authorizing the Department of Public Health to enter into partnerships to manufacture or distribute generic prescription drugs at lower prices to increase competition, address shortages, and improve patient access.

• Requires the Department to prioritize drugs for chronic and high-cost conditions, with at least one form of insulin included if a viable manufacturing pathway exists, and to set transparent prices without rebates except federally required ones.

• Mandates the Department consult with public agencies, health insurers, hospitals, and pharmacy benefit managers to identify target drugs and establish procurement volumes over multiyear periods.

• Requires two separate reports to the General Assembly: by July 1, 2023, assessing feasibility of direct manufacturing and governance structures; and by July 1, 2022, describing the status of targeted drugs and analyzing impact on competition, access, and costs.

• Amends the Freedom of Information Act to exempt nonpublic information and documents obtained under the Act from disclosure requirements, effective July 1, 2021.